



04-21-03

1646

Practitioner's Docket No. MWH-0303US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale et al.
Application No.: 09/811,285
I.A. Filing Date: April 13, 2000
I.A. No.: PCT/US00/10125

Group Art Unit: 1646
Examiner: Joseph F. Murphy

#14

FOR: ASSOCIATION OF BETA2-ADRENERGIC RECEPTOR HAPLOTYPES WITH DRUG
RESPONSE

RECEIVED

APR 23 2003

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AFTER MAILING OF FIRST OFFICE ACTION BUT WITHIN THREE MONTHS OF A
COMMUNICATION FROM A FOREIGN PATENT OFFICE (37 C.F.R. §1.97(c) & (e))

Enclosed herewith please find:

1. Identification of Time of Filing the Accompanying Information Disclosure Statement
2. Supplemental Information Disclosure Statement by Applicant Form PTO/SB/08B(1 page)
3. Copy of Listed Reference Accompanying Statement (2-Total)
4. Self-addressed stamped postcard

It is believed that no fee is required, but if that is incorrect you are hereby authorized to debit Deposit Account No. 50-1293 for any deficiency

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*

(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on April 18, 2003 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL533974842US addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Adam Gerbik
(type or print name of person mailing paper)
Adam Gerbik
Signature of person mailing

Date: 4/18/2003

Melodie W. Henderson
Signature of Practitioner

Reg. No.: 37,848
Tel. No.: 203-786-3421
Customer No.: 25106

Melodie W. Henderson
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/811,285
Filing Date	03/16/2001
First Named Inventor	Drysdale et. al.
Art Unit	1646
Examiner Name	Joseph F. Murphy
Attorney Docket Number	MWH-0303US2

Sheet

1

of

1

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Practitioner's Docket No. MWH-0303US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale et al.
Application No.: 09/811,285
I.A. Filing Date: April 13, 2000
I.A. No.: PCT/US00/10125

Group Art Unit No.: 1646
Examiner: Joseph F. Murphy

FOR: ASSOCIATION OF BETA2- ADRENERGIC RECEPTOR HAPLOTYPES
WITH DRUG RESPONSE

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Each item of information contained in the supplemental information disclosure statement submitted herewith was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made by Applicants, or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,
GENAISSANCE PHARMACEUTICALS, INC.

Date: 4/15/03
Tel. No. 203-786-3421
Fax No. 203-776-2788
Registration No. 37,848
m.henderson@genaisance.com

By: Melodie W. Henderson
Melodie W. Henderson



25106

PATENT TRADEMARK OFFICE